Dapagliflozin Prevents Heart Failure With Preserved Ejection Fraction by Inhibiting the Sodium/Hydrogen Exchanger
Man Liu, Hong Liu, Eunji Kim, Gyeoung-Jin Kang, Mitchell C. Neumann, Madeline Johnson, Ruthvika Murikinati, Samuel C. Dudley · 2026
Read Dapagliflozin Prevents Heart Failure With Preserved Ejection Fraction by Inhibiting the Sodium/Hydrogen Exchanger by Man Liu, Hong Liu, Eunji Kim, Gyeoung-Jin Kang, Mitchell C. Neumann, Madeline Johnson, Ruthvika Murikinati, Samuel C. Dudley (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13626939.txt.
Description
A class of diabetes drugs protects the heart even though their target protein is barely present in heart muscle, which raises a puzzle. Man Liu and co-authors chased the mechanism in 2026, focusing on a form of heart failure where the heart still pumps well but relaxes poorly. Low magnesium was their trigger for the disease, in mice and in human heart cells.
Three weeks of the drug dapagliflozin prevented the failure in mice on the low-magnesium diet. In cells, a sodium-hydrogen exchanger mimicked the harm when overactive, and the drug reversed that harm by blocking the exchanger. The drug also calmed immune cells in the heart. The authors conclude the exchanger, not the named target, explains this heart benefit.
Catalog record
| CREATOR | Man Liu, Hong Liu, Eunji Kim, Gyeoung-Jin Kang, Mitchell C. Neumann, Madeline Johnson, Ruthvika Murikinati, Samuel C. Dudley |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 48 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |